

MARKED-UP VERSION OF AMENDMENTS

Claims 15 and 16 have been amended as follows:

15. (Amended) A fusion protein according to claim [14] 18, wherein the polypeptide derived from herpesvirus outer membrane protein contains at least a signal sequence of the herpesvirus outer membrane protein.

16. (Amended) A recombinant live vaccine for anti-fowl Mycoplasma gallisepticum infection comprising as an effective ingredient a recombinant Avipox virus in which a DNA coding for the fusion protein according to any one of claims 2 through 8 and [14] 18 has been inserted, wherein the fusion protein is capable, upon administration into a host cell, of immunizing that cell against subsequent infection with Mycoplasma gallisepticum.

Serial Number: 09/147,052

Group Art Unit: 1645

REMARKS

Claims 2-11 and 15-19 are pending in this application.

Claims 15 and 16 have been amended.

The present claim amendments are made to conform dependencies following cancellation of claim 14.

If, for any reason, it is felt that this application is not now in condition for allowance, the Examiner is requested to contact Applicant's undersigned attorney at the telephone number indicated below.

In the event that this paper is not timely filed, Applicant respectfully petitions for an appropriate extension of time. The fees for such an extension or any other fees which may be due with respect to this paper, may be charged to Deposit Account No. 01-2340.

Respectfully submitted,

ARMSTRONG, WESTERMAN, HATTORI,
MCLELAND & NAUGHTON, LLP



Nicolas E. Seckel
Attorney for Applicants
Reg. No. 44,373

Atty. Docket No. 981167
1725 K Street, N.W., Suite 1000
Washington, DC 20006
Tel: (202) 659-2930
Fax: (202) 887-0357
NES:kah